4DMedical (ASX: 4DX) Pulls Back After Breakout Rally
4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.
Ansell (ASX: ANN): Margin Expansion and Operational Resilience Through Transition
Ansell (ASX: ANN) delivers double‑digit earnings growth, disciplined cost control, and strong cash conversion amid subdued market conditions, reinforcing margin resilience and balance‑sheet strength.
Sigma Healthcare (ASX: SIG): Integrated Scale, Relentless Momentum
Sigma Healthcare (ASX: SIG) delivers strong double‑digit growth and disciplined integration, positioning the merged Chemist Warehouse group for sustained expansion across domestic and international markets
Lumos Diagnostics (ASX: LDX): Enters Its Proof Phase as LDX Breaks the Downtrend
Lumos Diagnostics continues to expand its commercial footprint through FDA clearance, growing U.S. adoption, manufacturing partnerships, and paediatric research. The company now focuses on turning regulatory success and market access into recurring sales, broader reimbursement, and sustainable long-term growth.
Racura Oncology (ASX: RAC) - A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.
How Much Higher Can Recce Pharmaceuticals' (ASX: RCE) Share Price Go After the Recent Breakout?
Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.